Featured By Wall St News Network  : Cannabis Science ( CBIS - OTC )  - REPORT

Cannabis Science ( CBIS - OTC ) recently hit $0.065 on high volume topping 41 million shares, and is presently consolidating . We expect this company to again attempt a breakout above its yearly high. This company has the goods , a highly experienced  management team and a rapidly expanding market place. Serious investors should ride the next wave and place these shares on their BUY LIST  

Wall Street Daily

Cannabis Science Canada recently initiated operations , acquiring land and licenses from operators already doing business in Canada. We anticipate an aggressive expansion into Canada propelling the shares still higher. 

Disney Soars 40% - Strong Buy

Cannabis Science’s primary objective is to research and develop U.S. Food and Drug Administration (FDA)-approved, cannabinoid-based medicine to fight a number of targeted critical ailments, including various Cancers, Neurological Conditions, PTSD, Sleep Deprivation, Chronic Pain, HIV/AIDS, Autism, Parkinson’s Disease, Epilepsy, Chronic Obstructive Pulmonary Disease (COPD), and others. 

Crypto Crime Nets $40 Mill In Heist

Cannabis Science and its collaborators are well underway on a number of research projects targeting Lung Cancer, Pancreatic Cancer, Chronic Pelvic Pain, and Oro-bucco-lingual Dyskinesias. MORE NEWS ON CBIS

CANNABIS SCIENCE

 

WATCH THESE BTV SEGMENTS  BELOW                                                                     

On national TV Sat May 11 & Sun May 12, 2019 - BTV- Business Television visits three cannabis companies for your watchlist.  Full Episode
 
Trulieve Cannabis Corp. (TRUL:CSE) – Analyst, Matt Bottomley from Canaccord Genuity Group weighs in on this company that has 27 locations in Florida and is in the top three revenue producing, publicly traded cannabis stocks.  See Feature 

 

Biome Grow Inc. (BIO:CSE, BIOIF:OTCQB) – BTV visits this company focused on the underserviced Maritime provinces, who also entered a supply agreement with CBD Acres in the largest hemp-derived CBD deal to date.  See Feature

 
Captor Capital Corp. (CPTR:CSE, CPTRF:OTCQX) – BTV goes to its first California trade show to visit Captor’s wholly owned subsidiary, Chai Cannabis Co., focused on vertical integration with a seed to sale mentality. See Feature

 
BTV, a half-hour weekly investment program, profiles emerging companies across Canada and the US to bring investors information for their portfolio. With Hosts Taylor Thoen and Jessica Katrichak, BTV interviews experts, top analysts, plus features companies at their location giving investors an insightful business perspective. 


 

 

 

WallStreetResearcher.com is a subsidiary of Target Publishing Inc, and is a leading publisher of todays market and investment news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the financial markets and global economies. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts, which in turn delivers a variety of unique opportunXities for industry partnerships, corporate communications, market exposure and investment. The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility